Validation of a Soft Tissue Sarcoma Nomogram Using a National Cancer Registry

Sanjay P. Bagaria, Amy E. Wagie, Richard J. Gray, Barbara A Pockaj, Steven Attia, Elizabeth B Habermann, Nabil Wasif

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: A nomogram to predict disease-specific mortality (DSM) following surgery for soft tissue sarcoma (STS) has been developed by the Memorial Sloan Kettering Cancer Center (MSKCC). The goal of this study was to validate this nomogram by assessing discrimination and calibration at the population level using a national cancer database. Methods: Retrospective review of the Surveillance, Epidemiology, and End Results cancer registries identified patients undergoing surgery for STS from 1988 to 2011. Data for patient age, tumor size, tumor grade, histologic subtype, sex, primary tumor location, and tumor depth were entered into the nomogram calculator for each patient. Discrimination was quantified using a concordance index. Calibration was assessed by comparing quintiles of nomogram-predicted probabilities of disease-specific mortality (DSM) with American Joint Committee on Cancer (AJCC) stage DSM. Results: Overall, 9237 patients were identified with complete information needed for the nomogram. With a mean follow-up of 45 months, the concordance index for nomogram-predicted DSM with actual DSM was 0.74 for the entire cohort. For low- and high-grade tumors, this was 0.71 and 0.66, respectively. Kaplan–Meier curves showed better calibration for nomogram-predicted DSM when compared with AJCC staging. Conclusions: Our results validate the use of the MSKCC STS nomogram in the general population, with better predictive ability than AJCC staging. However, a concordance index of 0.74 suggests that further improvement in prognostication is needed, perhaps with biological markers or additional clinical variables.

Original languageEnglish (US)
JournalAnnals of Surgical Oncology
DOIs
StateAccepted/In press - Sep 9 2015

Fingerprint

Nomograms
Sarcoma
Registries
Neoplasms
Mortality
Calibration
Neoplasm Staging
Population
Epidemiology
Biomarkers
Databases

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Validation of a Soft Tissue Sarcoma Nomogram Using a National Cancer Registry. / Bagaria, Sanjay P.; Wagie, Amy E.; Gray, Richard J.; Pockaj, Barbara A; Attia, Steven; Habermann, Elizabeth B; Wasif, Nabil.

In: Annals of Surgical Oncology, 09.09.2015.

Research output: Contribution to journalArticle

@article{a825057aafc343818d4e8638628c4837,
title = "Validation of a Soft Tissue Sarcoma Nomogram Using a National Cancer Registry",
abstract = "Background: A nomogram to predict disease-specific mortality (DSM) following surgery for soft tissue sarcoma (STS) has been developed by the Memorial Sloan Kettering Cancer Center (MSKCC). The goal of this study was to validate this nomogram by assessing discrimination and calibration at the population level using a national cancer database. Methods: Retrospective review of the Surveillance, Epidemiology, and End Results cancer registries identified patients undergoing surgery for STS from 1988 to 2011. Data for patient age, tumor size, tumor grade, histologic subtype, sex, primary tumor location, and tumor depth were entered into the nomogram calculator for each patient. Discrimination was quantified using a concordance index. Calibration was assessed by comparing quintiles of nomogram-predicted probabilities of disease-specific mortality (DSM) with American Joint Committee on Cancer (AJCC) stage DSM. Results: Overall, 9237 patients were identified with complete information needed for the nomogram. With a mean follow-up of 45 months, the concordance index for nomogram-predicted DSM with actual DSM was 0.74 for the entire cohort. For low- and high-grade tumors, this was 0.71 and 0.66, respectively. Kaplan–Meier curves showed better calibration for nomogram-predicted DSM when compared with AJCC staging. Conclusions: Our results validate the use of the MSKCC STS nomogram in the general population, with better predictive ability than AJCC staging. However, a concordance index of 0.74 suggests that further improvement in prognostication is needed, perhaps with biological markers or additional clinical variables.",
author = "Bagaria, {Sanjay P.} and Wagie, {Amy E.} and Gray, {Richard J.} and Pockaj, {Barbara A} and Steven Attia and Habermann, {Elizabeth B} and Nabil Wasif",
year = "2015",
month = "9",
day = "9",
doi = "10.1245/s10434-015-4849-9",
language = "English (US)",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",

}

TY - JOUR

T1 - Validation of a Soft Tissue Sarcoma Nomogram Using a National Cancer Registry

AU - Bagaria, Sanjay P.

AU - Wagie, Amy E.

AU - Gray, Richard J.

AU - Pockaj, Barbara A

AU - Attia, Steven

AU - Habermann, Elizabeth B

AU - Wasif, Nabil

PY - 2015/9/9

Y1 - 2015/9/9

N2 - Background: A nomogram to predict disease-specific mortality (DSM) following surgery for soft tissue sarcoma (STS) has been developed by the Memorial Sloan Kettering Cancer Center (MSKCC). The goal of this study was to validate this nomogram by assessing discrimination and calibration at the population level using a national cancer database. Methods: Retrospective review of the Surveillance, Epidemiology, and End Results cancer registries identified patients undergoing surgery for STS from 1988 to 2011. Data for patient age, tumor size, tumor grade, histologic subtype, sex, primary tumor location, and tumor depth were entered into the nomogram calculator for each patient. Discrimination was quantified using a concordance index. Calibration was assessed by comparing quintiles of nomogram-predicted probabilities of disease-specific mortality (DSM) with American Joint Committee on Cancer (AJCC) stage DSM. Results: Overall, 9237 patients were identified with complete information needed for the nomogram. With a mean follow-up of 45 months, the concordance index for nomogram-predicted DSM with actual DSM was 0.74 for the entire cohort. For low- and high-grade tumors, this was 0.71 and 0.66, respectively. Kaplan–Meier curves showed better calibration for nomogram-predicted DSM when compared with AJCC staging. Conclusions: Our results validate the use of the MSKCC STS nomogram in the general population, with better predictive ability than AJCC staging. However, a concordance index of 0.74 suggests that further improvement in prognostication is needed, perhaps with biological markers or additional clinical variables.

AB - Background: A nomogram to predict disease-specific mortality (DSM) following surgery for soft tissue sarcoma (STS) has been developed by the Memorial Sloan Kettering Cancer Center (MSKCC). The goal of this study was to validate this nomogram by assessing discrimination and calibration at the population level using a national cancer database. Methods: Retrospective review of the Surveillance, Epidemiology, and End Results cancer registries identified patients undergoing surgery for STS from 1988 to 2011. Data for patient age, tumor size, tumor grade, histologic subtype, sex, primary tumor location, and tumor depth were entered into the nomogram calculator for each patient. Discrimination was quantified using a concordance index. Calibration was assessed by comparing quintiles of nomogram-predicted probabilities of disease-specific mortality (DSM) with American Joint Committee on Cancer (AJCC) stage DSM. Results: Overall, 9237 patients were identified with complete information needed for the nomogram. With a mean follow-up of 45 months, the concordance index for nomogram-predicted DSM with actual DSM was 0.74 for the entire cohort. For low- and high-grade tumors, this was 0.71 and 0.66, respectively. Kaplan–Meier curves showed better calibration for nomogram-predicted DSM when compared with AJCC staging. Conclusions: Our results validate the use of the MSKCC STS nomogram in the general population, with better predictive ability than AJCC staging. However, a concordance index of 0.74 suggests that further improvement in prognostication is needed, perhaps with biological markers or additional clinical variables.

UR - http://www.scopus.com/inward/record.url?scp=84941333998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941333998&partnerID=8YFLogxK

U2 - 10.1245/s10434-015-4849-9

DO - 10.1245/s10434-015-4849-9

M3 - Article

C2 - 26353762

AN - SCOPUS:84952871251

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

ER -